IPO registrations (S-1, F-1) · Registrants
Candel Therapeutics, Inc.
- SEC CIK
- 1841387 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2021-06-25, last 2021-07-26; 1 initial registration, 3 amendments
- Outcome
- Final prospectus filed 2021-07-28; declared effective 2021-07-26
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 117 KENDRICK STREET, SUITE 450, Needham, MA 02494
- EIN
- 52-2214851
- Ticker
- CADL (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Candel Therapeutics, Inc. on the corporate pages
Offering terms
- Final price
- $8.00 per share (424B4 filed 2021-07-28, an initial public offering)
- Shares sold
- 9,000,000
- Gross proceeds
- $72,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CADL
- Lead underwriters
- Jefferies; Credit Suisse (2,430,000 shares); BMO Capital Markets (1,800,000 shares); UBS (1,170,000 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: CANDEL THERAPEUTICS INC Fuzzy (name and state)
- Federal award recipient: CANDEL THERAPEUTICS, INC. Fuzzy (name and state)
- SEC filer: Candel Therapeutics, Inc. EXACT (CIK (EXACT))
- Person page: John J Canepa Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
Filings 7
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-06-25 | S-1 | S-1 (registration) | Candel Therapeutics, Inc. | 0001193125-21-200639 ↗ |
| 2021-07-16 | S-1/A | S-1/A (amendment) | Candel Therapeutics, Inc. | 0001193125-21-216891 ↗ |
| 2021-07-21 | S-1/A | S-1/A (amendment) | Candel Therapeutics, Inc. | 0001193125-21-219850 ↗ |
| 2021-07-26 | S-1/A | S-1/A (amendment) | Candel Therapeutics, Inc. | 0001193125-21-223611 ↗ |
| 2021-07-26 | EFFECT | EFFECT (declared effective) | Candel Therapeutics, Inc. | 9999999995-21-002918 ↗ |
| 2021-07-28 | 424B4 | 424B4 (final prospectus) | Candel Therapeutics, Inc. | 0001193125-21-227369 ↗ |
| 2022-08-12 | EFFECT | EFFECT (declared effective) | Candel Therapeutics, Inc. | 9999999995-22-002371 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-07-26 | S-1/A | registration statement | $8.00 | 9,000,000 | $72,000,000 | Nasdaq CADL | 4 | primary document; price sentence, shares headline, proceeds computed, cover names 4 | document ↗ | |
| 2021-07-28 | 424B4 | final prospectus | $8.00 | 9,000,000 | $72,000,000 | Nasdaq CADL | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 3, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Aguilar-Cordova Estuardo | Director; Director,Officer; Director,TenPercentOwner; TenPercentOwner | Chief Scientific Officer | 17 | 2021–2025 | |
| Aguilar Laura K. | Officer; TenPercentOwner | Chief Medical Officer | 15 | 2021–2025 | |
| Benz Edward J. JR | Director | 6 | 2021–2026 | ||
| Caffo Nathan | Officer | Chief Business Officer | 2 | 2021 | |
| Canepa John J | Officer | Chief Financial Officer | 3 | 2021–2022 | person page Fuzzy |
| Gandhi Shaan-Chirag C | Director | 1 | 2021 | ||
| Manning Paul B | Director; Director,TenPercentOwner | 15 | 2021–2026 | ||
| Martell Christopher | Director | 10 | 2021–2026 | ||
| Meirav Udi | Director | 1 | 2021 | ||
| Nguyen Diem | Director | 9 | 2021–2026 | ||
| SMITH ALAN E | Director | 1 | 2021 | ||
| Stewart Susan B. | Officer | Chief Regulatory Officer | 2 | 2021–2022 | |
| Tak Paul Peter | Director,Officer | Chief Executive Officer; President & CEO | 19 | 2021–2026 | |
| Barone Francesca | Officer | Chief Scientific Officer | 18 | 2022–2026 | |
| Tyagarajan Seshu | Officer | Chief Technology Officer; See Remarks | 19 | 2022–2026 | |
| Gaeta Renee | Director | 6 | 2022–2026 | ||
| Nabel Gary J. | Director | 7 | 2022–2026 | ||
| PAPA JOSEPH C | Director | 10 | 2022–2026 | ||
| Nichols William Garrett | Officer | Chief Medical Officer | 16 | 2022–2026 | |
| Amello Jason | Officer | Chief Financial Officer | 7 | 2022–2023 | |
| Loggia Nicoletta | Director | 8 | 2023–2026 | ||
| Schoch Charles | Officer | Chief Financial Officer; See Remarks | 10 | 2024–2026 | |
| Radhakrishnan Maha | Director | 3 | 2025–2026 | ||
| Sims Mark E. | Officer | Chief Commercial Officer | 2 | 2026 | |
| Zimmermann Martine | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | CANDEL THERAPEUTICS INC | MA | State business registries | name and state |
| Federal award recipient | CANDEL THERAPEUTICS, INC. | MA | Federal spending (USAspending) | name and state |
| SEC filer | Candel Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Candel Therapeutics, Inc. | MA | Trademarks (USPTO) | name and state |
| Person page | John J Canepa | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.